Drug Channels
DECEMBER 13, 2021
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from August 2021. The generic prescription market is being disrupted—but not by the big, bad spaceman from Seattle. Instead, consider how GoodRx is affecting patients, payers, and PBMs.
Drug Patent Watch
DECEMBER 17, 2021
Annual Drug Patent Expirations for NUPLAZID Nuplazid is a drug marketed by Acadia Pharms Inc and is included in two NDAs. It is available from one supplier. There are eighteen…. The post New patent for Acadia Pharms drug NUPLAZID appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Eye on FDA
DECEMBER 15, 2021
The COVID-19 pandemic is a rapidly changing landscape. We are long gone from the days of being threatened by a rampant Alpha virus to having several successive variants. It now appears that the very fast-spreading Omicron may become dominant over yesterday’s Delta variant. We now have multiple vaccines – mRNA and traditional in the U.S. and an even greater array outside the U.S.
Crown Bioscience
DECEMBER 16, 2021
In this post, we explore the differences between the terms high-content imaging (HCI), high-content screening (HCS), and high-content analysis (HCA), and why these automated and image-based high-throughput technologies are increasingly being adopted to generate data to facilitate preclinical studies and downstream go/no-go decision-making.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Channels
DECEMBER 15, 2021
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from August 2021. Charlotte Morabito at CNBC has put together “Why Pharmacies Overcharge,” an entertaining and provocative video on the pharmacy industry and its generic prescription pricing.
Drug Patent Watch
DECEMBER 16, 2021
Annual Drug Patent Expirations for XERAVA Xerava is a drug marketed by Tetraphase Pharms and is included in one NDA. There are two patents protecting this drug. This drug has…. The post New patent for Tetraphase Pharms drug XERAVA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
The Strateos Blog: Drug Discovery
DECEMBER 13, 2021
SynBioBeta 2021 – the Global Synthetic Biology Conference – will take place between January 25th - 27th 2022 in Oakland, California. Strateos’ own Daniel Rines, Ph.D., Senior Director, R&D Strategy, will be delivering a presentation highlighting how Strateos' smart lab platform accelerated riboswitch engineering to develop novel biosensors.
Drug Channels
DECEMBER 16, 2021
This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Outlook 2022. Hope you can join me! Click here to see the original post and comments from September 2021. Cardinal Health recently released the annual report for its 2021 fiscal year, which ended on June 30. See the links below. Today, I delve into the financials behind Cardinal’s relationship with its largest customer, CVS Health.
Drug Patent Watch
DECEMBER 17, 2021
Annual Drug Patent Expirations for LENVIMA Lenvima is a drug marketed by Eisai Inc and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Eisai Inc drug LENVIMA appeared first on DrugPatentWatch - Make Better Decisions.
Sygnature Discovery
DECEMBER 17, 2021
2021 is nearly over – and what a year it’s been for Sygnature! From key appointments to new investment and growth across the pond, there have been plenty of reasons to get out the party poppers despite the ongoing pandemic (in a safe fashion, obviously). Let’s remind ourselves of a great 12 months… The successes started early when we were named Company of the Year at the slightly delayed 2020 Bionow Annual Awards in February.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
The Strateos Blog: Drug Discovery
DECEMBER 13, 2021
We are excited to share that Strateos’ SVP of Strategy & Operations, Daniel Sipes, will be delivering a presentation entitled Accelerating Medicinal Chemistry Cycle Times Through Cloud-Accessible Smart Automated Labs at the upcoming 2022 Society for Laboratory Automation and Screening Conference & Exhibition between February 5-9th. SLAS 2022 is set to be an exciting conference where scientists can come together to learn about the innovative technologies transforming the way life s
Drug Channels
DECEMBER 17, 2021
This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Drug Channels Outlook 2022. See you soon! Click here to see the original post and comments from September 2021. Sometimes, a little knowledge can be a bad thing. I want to share with you, dear reader, the strange but true tale of my recent foray into the wonderful world of hospital price transparency for routine lab services.
Drug Patent Watch
DECEMBER 17, 2021
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are six…. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 17, 2021
Annual Drug Patent Expirations for TRUDHESA Trudhesa is a drug marketed by Impel Neuropharma and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent for Impel Neuropharma drug TRUDHESA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
DECEMBER 17, 2021
Annual Drug Patent Expirations for ROCKLATAN Rocklatan is a drug marketed by Aerie Pharms Inc and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Aerie Pharms drug ROCKLATAN appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 17, 2021
Annual Drug Patent Expirations for GOPRELTO Goprelto is a drug marketed by Genus Lifesciences and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Genus Lifesciences drug GOPRELTO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 17, 2021
Annual Drug Patent Expirations for RHOPRESSA Rhopressa is a drug marketed by Aerie Pharms Inc and is included in one NDA. It is available from one supplier. There are twelve…. The post New patent for Aerie Pharms drug RHOPRESSA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 16, 2021
Annual Drug Patent Expirations for BYSTOLIC Bystolic is a drug marketed by Allergan and is included in one NDA. It is available from three suppliers. There is one patent protecting…. The post New patent expiration for Allergan drug BYSTOLIC appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 16, 2021
Annual Drug Patent Expirations for DAURISMO Daurismo is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier. There are three patents protecting…. The post New patent for Pfizer drug DAURISMO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 16, 2021
Annual Drug Patent Expirations for TRIKAFTA+%28COPACKAGED%29 Trikafta (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Vertex Pharms drug TRIKAFTA (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 16, 2021
Annual Drug Patent Expirations for MOVANTIK Movantik is a drug marketed by Redhill and is included in one NDA. It is available from three suppliers. There are six patents protecting…. The post New patent for Redhill drug MOVANTIK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 14, 2021
Annual Drug Patent Expirations for QINLOCK Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent for Deciphera Pharms drug QINLOCK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 14, 2021
Annual Drug Patent Expirations for TEFLARO Teflaro is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are five patents protecting…. The post New patent expiration for Allergan drug TEFLARO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 14, 2021
Annual Drug Patent Expirations for CINVANTI Cinvanti is a drug marketed by Heron Theraps Inc and is included in one NDA. It is available from one supplier. There are eight…. The post New patent for Heron Theraps drug CINVANTI appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 13, 2021
Annual Drug Patent Expirations for EVEKEO+ODT Evekeo Odt is a drug marketed by Arbor Pharms Llc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Arbor Pharms drug EVEKEO ODT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 14, 2021
This chart shows the drugs with the most patents in Norway. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Norway? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 13, 2021
This chart shows the pharmaceutical companies with the most patents in Brazil. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Brazil? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 16, 2021
This chart shows the pharmaceutical companies with the most patents in Norway. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Norway? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 17, 2021
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the…. The post Which pharmaceutical companies have supplementary protection certificates in the most countries? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 15, 2021
This chart shows the pharmaceutical companies with the most patents in Croatia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Croatia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 12, 2021
This chart shows the pharmaceutical companies with the most patents in Taiwan. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Taiwan? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 11, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Sweden. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Sweden? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
DECEMBER 14, 2021
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from July 2021. Since 2012, Drug Channels has examined commercial drug spending using the annual trend reports published by the largest PBMs. This year, we review 2020 data on commercial plan sponsor clients of CVS Health and Express Scripts along with two smaller PBMs—Navitus and WellDyne.
Expert insights. Personalized for you.
98 
Let's personalize your content